Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT07013565 · New York Medical College

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

(ACCELERATE)

What this study is about

Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of how long patients live.

View original scientific description

Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival. This clinical trial will investigate if a new FDA approved medication called Nivolumab (NIVO) (which is a checkpoint blockade immunotherapy) combined with chemotherapy based on the patients risk status to get the patient into the best response possible. Then patients will receive lower doses of chemoimmunotherapy and allogeneic stem cell transplantation (stem cells from another person). The investigators this this new treatment will improve survival rates in this high-risk population of patients.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Patients must weigh ≥10 kilograms at the time of study enrollment.
  • Patients with relapsed or refractory histologically or cytologically proven ALK-positive anaplastic large cell lymphoma meeting Low or High Risk Criteria: Low Risk Cohort (LR cohort):
  • Any patient with FIRST RELAPSE \> ONE YEAR from initial diagnosis of de novo ALK+ ALCL,
  • Common histology,
  • CD3 negative, AND
  • No prior exposure to vinblastine (VBL). High-Risk Cohort (HR cohort):
  • Any patient with RELAPSED OR PROGRESSIVE DISEASE less than ONE YEAR from initial diagnosis of de novo ALK+ ALCL,
  • Small cell/histiocytic histology,
  • CD3 positive (homogeneous staining of CD3 positive T-cells)
  • Patients must have adequate organ function.
  • Patients must have performance status 60 or above.

Exclusion criteria

  • ALK-NEGATIVE anaplastic large cell lymphoma.
  • Patients with active leptomeningeal disease (lymphoma cells in CSF).
  • Previous treatment with vinblastine (only in patients in the LR cohort).
  • Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarche.
  • Lactating females unless they have agreed not to breastfeed their infants.
  • Patients with Down syndrome.
  • Any patient with uncontrolled infection prior to study entry.
  • Any patient known to have primary or acquired immunodeficiency and/or prior solid organ transplant.

Where

  • Valhalla, New York

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced May 20, 2026 · Source of record for eligibility and locations

📊
1 of 20 participants interested
5% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Valhalla

New York

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Lymphoma Trials by City

Browse all lymphoma clinical trials in these cities — not just this study.

Looking for Anaplastic Large Cell Lymphoma, ALK-Positive Treatment in Valhalla?

Join others in New York exploring innovative treatment options through clinical research

Anaplastic Large Cell Lymphoma, ALK-Positive Treatment Options in Valhalla, New York

If you're searching for Anaplastic Large Cell Lymphoma, ALK-Positive treatment in Valhalla, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Valhalla and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Anaplastic Large Cell Lymphoma, ALK-Positive. All study-related care is provided at no cost to participants.

Local Sites
1 locations in New York
Now Enrolling
Up to 20 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Anaplastic Large Cell Lymphoma, ALK-Positive?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Anaplastic Large Cell Lymphoma, ALK-Positive

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Anaplastic Large Cell Lymphoma, ALK-Positive Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT07013565. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.